Rujin Cheng
Rujin joined Juvena Therapeutics as a Principle Scientist, Protein Sciences to work on Juvena’s growing drug discovery platform. Rujin obtained his B.S. in Biotechnology (2011) and M.S. in Chemistry (2014) from Wuhan University of Technology, and earned his Ph.D in Biochemistry from the Department of Chemistry and Biochemistry at the University of Delaware (2020). During his Ph.D, Rujin utilized multiple approaches to make selenocysteine enriched selenoproteins by genetic Sec incorporation and by selenoprotein/selenopeptide ligation; he studied the function of ER membrane bound selenoproteins that are also IDPs such as the molecular interaction between p97 and SELENOS, and auto-proteolytic activity of SELENOK. In addition, Rujin extensively characterized proteins that are genetically encoded with selenocysteine, non-natural amino acids using intact MS, tandem MS including cross-linking MS and contributed to multiple publications.
Before joining Juvena Therapeutics, Rujin worked at NGM Biopharmaceuticals as a Sr. Scientist, Protein Sciences. During his time at NGM, Rujin worked on biologics drug discovery and development across various different formats, including hexameric IgG for ocular indications, bispecific T cell engagers for IO, bispecific LTBR agonist, he also played a key role as project co-lead in advancing several bispecific ADC programs from proof of concept to promising drug candidates. Rujin built various higher throughput BsAb purification and characterization platforms, which facilitated BsAb matrix screening, lead identification and optimization, he combined antibody engineering and process development to address complex challenges in scale up production and early developability determination.
Rujin contributed to more than 15 publications (co-author and first-author) and is a named inventor on 4 drug development patents.
Learn more about Rujin
